Muscarinic Acetylcholine Receptor M1 Antagonists Pipeline Research Report 2024: Comprehensive Insights on 8+ Drugs Featuring Tonix Pharmaceuticals, BMS, WinSanTor, and ApnimedGlobeNewsWire • 7h
Tonix Pharmaceuticals Announces Poster Presentation at the American College of Rheumatology (ACR) Convergence 2024 Annual MeetingGlobeNewsWire • 11/13/24
Tonix Pharmaceuticals Announces Peer-Reviewed Publication in mSphere Journal Highlighting the Tolerability of Company's Single-Dose Mpox and Smallpox Vaccine Candidate TNX-801, in Immune-Compromised AnimalsGlobeNewsWire • 11/13/24
Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024GlobeNewsWire • 11/01/24
Tonix Pharmaceuticals Announces Submission of the TNX-102 SL New Drug Application (NDA) for Fibromyalgia to the U.S. Food and Drug Administration (FDA)GlobeNewsWire • 10/16/24
Tonix Pharmaceuticals Announces AI Collaboration with X-Chem to Develop Broad-Spectrum AntiviralsGlobeNewsWire • 10/08/24
The Rush for Non-Addictive Painkillers to Counter the Opioid Crisis Puts Two Companies Close to FDA DecisionsAccesswire • 10/01/24
Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace® SymTouch® to Treat MigrainesGlobeNewsWire • 09/27/24
Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra® to Treat MigrainesGlobeNewsWire • 09/19/24
New Hope for Mpox? How TNX-801 Could Meet the WHO's Vaccine Targets for a Safer, Single-Dose SolutionAccesswire • 09/18/24
Tonix Pharmaceuticals Announces That its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO's Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health EmergencyGlobeNewsWire • 09/16/24
Tonix Pharmaceuticals Launches National Awareness Campaign on the Impact of Gastroparesis or Stomach Paralysis on the Absorption of Oral Migraine Medications at PAINWeekGlobeNewsWire • 09/06/24
As Research into Pain Accelerates, a Newly Recognized Type of Pain Comes to the Forefront - Tonix Targets it with FDA-Fast Track-Designated TNX-102 SLAccesswire • 09/04/24
Tonix Pharmaceuticals Presented Data from Two Posters on TNX-102 SL for Reduction of Acute Stress Reaction and Prevention of PTSD and One Poster for Wound Healing at the 2024 Military Health System Research Symposium (MHSRS)GlobeNewsWire • 08/29/24
Tonix Pharma Collaborates With World's Largest Vaccine Manufacturer For Mpox VaccineBenzinga • 08/26/24
Tonix Pharmaceuticals and Bilthoven Biologicals to Collaborate on Advancing Development of Tonix's Mpox Vaccine, TNX-801GlobeNewsWire • 08/26/24
Modern Twist to Centuries-Old Smallpox Vaccine Poised to Combat Deadly Mpox Strain as WHO Declares Global EmergencyAccesswire • 08/23/24
Tonix Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational HighlightsGlobeNewsWire • 08/19/24
Tonix Pharmaceuticals Provides Update on the Development of Its Single Dose Live Attenuated Virus Vaccine Candidate for Mpox, TNX-801, as WHO Declares Mpox Outbreak a Global Health EmergencyGlobeNewsWire • 08/16/24
FDA Recognizes Fibromyalgia as a 'Serious Condition' And Fast-Tracks New Drug CandidateAccesswire • 08/01/24
